Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMe2415376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infrequent Zoledronate - Small Individual Gain, Larger Population Gain.
N Engl J Med
January 2025
From INSERM Unité Mixte de Recherche 1033, Université Claude Bernard-Lyon1, Hôpital E. Herriot, Lyon, France.
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age.
N Engl J Med
January 2025
From the Department of Medicine, University of Auckland, Auckland, New Zealand (M.J.B., Z.N., A.M., C.G., V.P., B.M., A.G., I.R.R., G.G., A.H.); the Department of Psychology, Stanford University, Stanford, CA (C.G.); and the Department of Radiology, Starship Hospital, Auckland, New Zealand (S.B.).
Background: Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate administration would prevent vertebral fractures in early postmenopausal women is unknown.
Methods: We conducted a 10-year, prospective, double-blind, randomized, placebo-controlled trial involving early postmenopausal women (50 to 60 years of age) with bone mineral density T scores lower than 0 and higher than -2.
Effect of zoledronic acid and pamidronate on renal function.
J Oncol Pharm Pract
September 2024
Department of Pharmacy, Rush University Medical Center; Chicago, IL, USA.
Background: There is limited data on the effect bisphosphonates have on renal function and the use of bisphosphonates in patients with baseline renal dysfunction.
Objective: The purpose of this study was to determine the incidence of acute kidney injury (AKI) in patients after receiving zoledronic acid or pamidronate.
Methods: A retrospective cohort analysis was conducted of patients who received one dose of a bisphosphonate, either zoledronic acid or pamidronate.
Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone.
Ther Adv Endocrinol Metab
November 2023
Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel Hashomer, Israel.
Background: Teriparatide (TPTD) should be followed by an antiresorptive to maximize bone mineral density gain and anti-fracture protection. Infrequent zoledronic acid (ZOL) administration has demonstrated effectiveness. The duration of ZOL effect following TPTD is unknown.
View Article and Find Full Text PDFUnmasking the enigma: A case of Fumarate Hydratase-deficient renal cell carcinoma.
Int J Surg Case Rep
December 2023
Department of Medical Oncology, The Aga Khan University Hospital, Pakistan.
Introduction: Fumarate Hydratase-deficient-renal cell carcinoma (FH-dRCC) is an uncommon and extremely aggressive variant of renal cell carcinoma (RCC) resulting from inactivating mutations in the tumor suppressor gene, fumarate hydratase (FH).
Case Presentation: We report a case of a young male who presented with the complaint of painless hematuria. Upon workup, he was found to have a renal mass with bony metastases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!